Greg Harrison
Stock Analyst at B of A Securities
(4.37)
# 269
Out of 5,182 analysts
106
Total ratings
55%
Success rate
18.92%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $44 → $41 | $28.00 | +46.43% | 10 | Apr 21, 2026 | |
| UTHR United Therapeutics | Maintains: Neutral | $569 → $626 | $571.35 | +9.57% | 6 | Mar 31, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $46 → $51 | $26.65 | +91.37% | 3 | Mar 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $495 → $558 | $427.38 | +30.56% | 8 | Feb 13, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $13.48 | +122.55% | 3 | Oct 27, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $42.12 | -26.40% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $9.37 | +113.45% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $71.11 | -19.84% | 7 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $309.49 | +45.40% | 6 | Aug 1, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $0.37 | +2,890.76% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $8.62 | +306.03% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $35.61 | +54.45% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $19 | $3.48 | +445.98% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $39.21 | -5.64% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $11.12 | +133.81% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $40.95 | -51.16% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.54 | -2.60% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $30.33 | +31.88% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $65.95 | +13.72% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $13.20 | +36.36% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $32.72 | -63.33% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.12 | +1,158.39% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $3.00 | +400.00% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $14.60 | -79.45% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.92 | +7,468.39% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $14.16 | +281.36% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $85.04 | +5.83% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Apr 21, 2026
Maintains: Buy
Price Target: $44 → $41
Current: $28.00
Upside: +46.43%
United Therapeutics
Mar 31, 2026
Maintains: Neutral
Price Target: $569 → $626
Current: $571.35
Upside: +9.57%
Mineralys Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $46 → $51
Current: $26.65
Upside: +91.37%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Sector Perform
Price Target: $495 → $558
Current: $427.38
Upside: +30.56%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $13.48
Upside: +122.55%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $42.12
Upside: -26.40%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $9.37
Upside: +113.45%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $71.11
Upside: -19.84%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $309.49
Upside: +45.40%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $0.37
Upside: +2,890.76%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $8.62
Upside: +306.03%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $35.61
Upside: +54.45%
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $3.48
Upside: +445.98%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $39.21
Upside: -5.64%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $11.12
Upside: +133.81%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $40.95
Upside: -51.16%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.54
Upside: -2.60%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $30.33
Upside: +31.88%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $65.95
Upside: +13.72%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $13.20
Upside: +36.36%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $32.72
Upside: -63.33%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.12
Upside: +1,158.39%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $3.00
Upside: +400.00%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $14.60
Upside: -79.45%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $0.92
Upside: +7,468.39%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $14.16
Upside: +281.36%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $85.04
Upside: +5.83%